ReviewPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]2008
Biological approaches to therapy of pancreatic cancer.
Review in Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Trial
- Review
- Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.Molecular and clinical oncology · 2016Article
- Gene therapy in pancreatic cancer.World journal of gastroenterology · 2014Review
- Article
- Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation.Medical oncology (Northwood, London, England) · 2012Article
- Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2012Review
- Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2011Article
- hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.Cancer immunology, immunotherapy : CII · 2011Article
- Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.Cancers · 2010Article
- Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2010Article
- Novel therapies for pancreatic cancer: setbacks and progress.Future oncology (London, England) · 2010Article
- Targeted drug delivery in pancreatic cancer.Biochimica et biophysica acta · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Pancreatic cancer is a lethal disease and notoriously difficult to treat. Only a small proportion is curative by surgical resection, whilst standard chemotherapy for patients with advanced disease has only modest effect with substantial toxicity. Clearly there is a need for the continual development of novel therapeutic agents to improve the current situation. Improvement of our understanding of the disease has generated a large number of studies on biological approaches targeting the molecular abnormalities of pancreatic cancer, including gene therapy and signal transduction inhibition, antiangiogenic and matrix metalloproteinase inhibition, oncolytic viral therapy and immunotherapy. This article provides a review of these approaches, both investigated in the laboratories and in subsequent clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.